What is AxoGen?
Founded in 2002, AxoGen specializes in the development and production of cutting-edge surgical solutions designed to address peripheral nerve injuries. The company's comprehensive product portfolio includes innovative offerings such as the Avance Nerve Graft for bridging severed nerves, the AxoGuard Nerve Connector for tensionless nerve repair, and the AxoGuard Nerve Protector for safeguarding injured peripheral nerves. Complementing these surgical devices, AxoGen also provides diagnostic tools like the AcroVal neurosensory testing system and the AxoTouch discriminator. AxoGen's solutions are distributed to hospitals, surgery centers, and military medical facilities across North America, Europe, and other international markets, serving a critical need in peripheral nerve repair procedures.
How much funding has AxoGen raised?
AxoGen has raised a total of $99.3M across 8 funding rounds:
Series B
$7.8M
Series C
$12.1M
Debt
$2.6M
Debt
$3.7M
Debt
$3M
Stock Offering
$18M
Share Placement
$17.1M
Debt
$35M
Series B (2006): $7.8M with participation from Springboard Capital
Series C (2007): $12.1M led by Accuitive Medical Ventures, Cardinal Partners, DeNovo Ventures, and Springboard Capital II
Debt (2009): $2.6M, investors not publicly disclosed
Debt (2011): $3.7M, investors not publicly disclosed
Debt (2011): $3M, investors not publicly disclosed
Stock Issuance/Offering (2013): $18M, investors not publicly disclosed
Share Placement (2015): $17.1M led by Essex Woodlands
Debt (2020): $35M supported by Oberland Capital Management LLC
Key Investors in AxoGen
Accuitive Medical Ventures
Accuitive Medical Ventures is a venture capital firm specializing in revolutionary medical device technology investment opportunities, with a focus on early-stage companies and those developed within The Innovation Factory.
Cardinal Partners
Cardinal Partners is a venture capital partnership exclusively focused on healthcare investing since 1996, specializing in early-stage financing rounds as a lead investor.
Essex Woodlands
EW Healthcare Partners (formerly Essex Woodlands) is a healthcare growth equity firm that invests in companies across the US and Europe, focusing on pharmaceuticals, MedTech, and tech-enabled services.
What's next for AxoGen?
The recent major strategic investment in AxoGen, following a history of diverse financing including debt and equity rounds, suggests a strong trajectory for scaling operations and further innovation. This capital is likely to fuel advancements in their surgical solutions for peripheral nerve injuries, potentially expanding their product pipeline and enhancing their diagnostic capabilities. The company's established distribution network across North America and Europe positions it well for increased market penetration and the adoption of its technologies by a wider range of medical professionals. AxoGen's focus on a specialized, high-impact medical niche indicates a strategic direction aimed at solidifying its leadership in nerve repair and regeneration.
See full AxoGen company page
